title: Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.
abstract: BACKGROUND
  The oligomeriztion of α-synuclein (α-syn) into ordered assemblies is associated with the symptoms of Parkinson's Disease (PD). Yet, it is still debatable whether oligomers are formed as part of a multistep process towards amyloid fibril formation or alternatively as "off-pathway" aggregates.
  
  
  METHODS
  100μM α-syn was incubated with decreasing amounts of cinnamon extract precipitation (CEppt). The fibril formation was measured using spectroscopy and microscopy analyses and oligomers were detected using western blot analysis. The secondary structure of the protein was analyzed using CD. Drosophila brains were studied using immunostaining and confocal microscopy.
  
  
  RESULTS
  Here we probed the inhibition pattern of oligomeric and fibrillar forms of α-syn, using a natural substance, CEppt which was previously shown to effectively inhibit aggregation of β-amyloid polypeptide. We demonstrated that CEppt has a differential inhibitory effect on the formation of soluble and insoluble aggregates of α-synuclein in vitro. This inhibition pattern revokes the possibility of redirection to "off-pathway" oligomers. When administering to Drosophila fly model expressing mutant A53T α-syn in the nervous system, a significant curative effect on the behavioral symptoms of the flies and on α-syn aggregation in their brain was observed.
  
  
  CONCLUSIONS
  We conclude that CEppt affects the process of aggregation of α-syn without changing its secondary structure and suggest that increasing amounts of CEppt slow this process by stabilizing the soluble oligomeric phase. When administered to Drosophila fly model, CEppt appears to have a curative effect on the defective flies.
  
  
  CONCLUSIONS
  Our results indicate that CEppt can be a potential therapeutic agent for PD.
authors.affiliation: Department Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv 69978, Israel.
authors.forename: Ronit
authors.initials: R
authors.lastname: Shaltiel-Karyo
authors.forename: Dan
authors.initials: D
authors.lastname: Davidi
authors.forename: Moran
authors.initials: M
authors.lastname: Frenkel-Pinter
authors.forename: Michael
authors.initials: M
authors.lastname: Ovadia
authors.forename: Daniel
authors.initials: D
authors.lastname: Segal
authors.forename: Ehud
authors.initials: E
authors.lastname: Gazit
mesh_terms: D000682:Amyloid / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000818:Animals; D030801:Animals, Genetically Modified; D016466:CHO Cells; D002935:Cinnamomum zeylanicum / Q000737:chemistry; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004330:Drosophila / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008517:Phytotherapy / Q000379:methods; D010936:Plant Extracts / Q000627:therapeutic use*; D055503:Protein Multimerization / Q000187:drug effects* / Q000235:genetics; D051844:alpha-Synuclein / Q000235:genetics / Q000378:metabolism*
chemical_list: D000682:Amyloid; D010936:Plant Extracts; D051844:alpha-Synuclein